(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 August 2014 (28.08.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/130879 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/US2014/017810

(22) International Filing Date:
21 February 2014 (21.02.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/768,368 22 February 2013 (22.02.2013) US

(71) Applicants: **STEM CENTRX, INC.** [US/US]; 450 East Jamie Court, South San Francisco, California 94080 (US). **SPIROGEN SÀRL** [CH/CH]; c/o Michael Forer, Rue Saint-Pierre 2, CH-1003 Lausanne (CH).

(72) Inventors: **TORGOV, Michael**; Apt. #B, 7027 Ramsgate Pl., Los Angeles, California 90045 (US). **HOWARD, Philip Wilson**; Medimmune Spirogen Business Unit, QMB Innovation Centre, 42 New Road, London, Greater London E1 2AX (GB).

(74) Agents: **MEIGS, Julie Broadus** et al.; Womble Carlyle Sandridge & Rice, LLP, P.O. Box 7037, Atlanta, Georgia 30357-0037 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

[Continued on next page]

(54) Title: NOVEL ANTIBODY CONJUGATES AND USES THEREOF

(57) Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.

Biochemical Characteristics of Selected DLL3 Modulators

Clone	Bin	Domain	Affinity (nM)	Cyno XR	Mouse & Rat XR
SC16.4	F	EGF4	0.5[F]	N.D.	Yes
SC16.8	A	EGF5	0.5[F]	N.D.	Yes
SC16.10	E	EGF2	4.0[F]	N.D.	No
SC16.13	B	EGF2	2.0[B]	No[Y]	No
SC16.15	G	N-terminal	0.5[B]	Yes[B]	Yes
SC16.25	C	N-terminal	0.2[B]	Yes[B]	No
SC16.34	D	DSL	0.2[B]	Yes[B]	Yes
SC16.39	I	EGF6	1.0[F]	N.D.	Yes
SC16.46	A	EGF1	0.5[F]	No[Y]	Yes
SC16.51	H	N-terminal	2.0[F]	Yes[B]	Yes
SC16.56	D	DSL	1.0[B]	Yes[B]	Yes
SC16.65	B	EGF2	0.9[B]	No[B]	No
SC16.67	D	EGF3	0.5[F]	Yes[Y]	No

[B] Biacore; [F] ForteBio; [Y] Yeast Display

FIG. 5

WO 2014/130879 A3

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
16 October 2014